Abstract
Qternmet XR (R) (FDA approval, May 2019) is a multitarget anti-diabetic drug combination composed of metformin (MET), saxagliptin (SAX) and dapagliflo......
小提示:本篇文献需要登录阅读全文,点击跳转登录